Matinas BioPharma August 2024 Corporate Presentation

Loading viewer...

investor_presentation

Format: PDF investor_presentation

Matinas BioPharma's presentation outlines its lipid nanocrystal (LNC) delivery platform designed to enhance therapeutic value across oncology and inflammation. The company highlights its Phase 3-ready ORALTO candidate for invasive aspergillosis treatment and discusses LNC capabilities for improved oral delivery, reduced toxicity, and expanded cargo potential including small molecules and oligonucleotides.

Browse all investor_presentations →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Matinas BioPharma

View all →

Matinas BioPharma Corporate Presentation 2023 | MTNB Investor

investor_presentation

28 Pages

Similar investor_presentations from other companies

Browse all →

Allscripts Healthcare Solutions Investor Presentation — July 2020

investor_presentation

20 Pages

Allscripts Healthcare Solutions

F-Secure Investor Presentation Q4 2022

investor_presentation